ライフサイエンスコーパス: DNA antibody

1 nic for the heavy chain of a pathogenic anti-DNA antibody.

2 ce transgenic for the heavy chain of an anti-DNA antibody.

3 spital because of a high serum level of anti-DNA antibody.

4 hromes and a monoclonal anti-double-stranded DNA antibody.

5 nic for the heavy chain of a pathogenic anti-DNA antibody.

6 is, deforming arthropathy and increased anti-DNA antibodies.

7 , which is expressed on anti-double-stranded-DNA antibodies.

8 ansgenic mice whose transgenes code for anti-DNA antibodies.

9 uate predictors of the pathogenicity of anti-DNA antibodies.

10 tinuclear antibodies or anti-double-stranded DNA antibodies.

11 terized by the production of double-stranded DNA antibodies.

12 icient 3H9 mice spontaneously generated anti-DNA antibodies.

13 esearch and point-of-care monitoring of anti-DNA antibodies.

14 ) treated with pathogenic, noncomplexed anti-DNA antibodies.

15 DNA-derived peptides and peptides from anti-DNA antibodies.

16 is recognized by both murine and human anti-DNA antibodies.

17 diotypic antibodies and anti-single-stranded DNA antibodies.

18 mplementemia, and/or elevated levels of anti-DNA antibodies.

19 e presence of serum anti-double-stranded (ds)DNA antibodies (Abs), whereas nonautoimmune individuals

20 is the presence of anti-double-stranded (ds)DNA antibodies (Abs).

21 orbent assay plates was used to measure anti-DNA antibody activity.

22 itis, and patients with anti-double-stranded DNA antibodies (adjusted HR approximately 2.0 for each o

23 ipients caused a lupuslike disease with anti-DNA antibodies, an immune complex glomerulonephritis and

24 Both human monoclonal anti-DNA antibodies and antibodies affinity purified from the

25 bromocriptine led to reduced titers of anti-DNA antibodies and diminished IgG deposition in kidneys

26 ly activated the production of antichromatin/DNA antibodies and dramatically accelerated renal diseas

27 nal because it helps B cells to produce anti-DNA antibodies and express more CD80 (B7-1) on their sur

28 oped systemic autoimmunity, characterized by DNA antibodies and immune complex glomerulonephritis.

29 These mice develop high-titer anti-DNA antibodies and immune complex-mediated nephritis and

30 ion (PBSCT) prevented the production of anti-DNA antibodies and the development of lupus nephritis in

31 a significant change in anti-double-stranded DNA antibody and complement levels.

32 is demonstrated by single-step labelling of DNA, antibodies and proteins, as well as applications in

33 eived injections of radiolabeled murine anti-DNA antibody, antibody with no DNA binding capability, a

34 We found that high-affinity anti-DNA antibodies are a major component of the intrathecal

35 Anti-DNA antibodies are associated with glomerulonephritis in

36 Anti-double-stranded (ds) DNA antibodies are not only an important diagnostic mark

37 Anti-DNA antibodies are produced transiently, mainly during p

38 Anti-DNA antibodies are regulated in normal individuals but a

39 Lupus-associated IgG anti-double-stranded DNA antibodies are thought to be pathogenic in the kidne

40 gnificant gene up-regulation induced by anti-DNA antibodies as determined by microarray analysis was

41 tly reduced the renal deposition of the anti-DNA antibody at 48 h (1.53%, P < 0.00001) and at 7-8 d (

42 rbB2 gene product, was recognized by an anti-DNA antibody, B3, and importantly by two classical DNA-b

43 ytes including, but not limited to, glucose, DNA, antibodies, bacteria and viruses.

44 body could provide a mechanism by which anti-DNA antibodies bind diverse host ligands, and thereby co

45 g recent reports that pathogenic murine anti-DNA antibodies bind to alpha-actinin, it was obviously o

46 on of IgM, IgG, and IgA, as well as IgM anti-DNA antibodies, but was not necessary for B cell stimula

47 tibodies, deposition of anti-double-stranded DNA antibody complexes, complement activation, and immun

48 n and the generation of anti-double-stranded-DNA antibodies, critically aggravating atherosclerosis l

49 It has been shown that anti-DNA antibodies cross-react with bacterial polysaccharide

50 Levels of anti-double-stranded DNA antibodies decreased by a median of 47% in patients

51 boration, production of anti-double-stranded DNA antibodies, deposition of anti-double-stranded DNA a

52 A unique subset of anti-DNA antibodies enters living cells, interacts with DNase

53 The anti-DNA antibody fragment 3E10 Fv has received attention as

54 s in the heavy chain variable region of anti-DNA antibodies from lupus-prone (NZB/NZW F1) mice.

55 tibodies >/=1:80 and/or anti-double-stranded DNA antibodies >/=30 IU/ml) at baseline was retrospectiv

56 to be correlated to the Arg content of anti-DNA antibody hypervariable loops.

57 tion of 1:120 or more), anti-double-stranded DNA antibodies in 55 percent, anti-Ro antibodies in 47 p

58 as sufficient to induce anti-double-stranded DNA antibodies in a murine model of drug-induced lupus,

59 ed in prompt production of IgM antidenatured DNA antibodies in C57BL/6xDBA/2 F1 mice.

60 y to quantify over the course of 30 min anti-DNA antibodies in fresh human serum without background r

61 ower concentrations of DNA complexed to anti-DNA antibodies in human serum, we found a maximal enhanc

62 vels of all immunoglobulin isotypes and anti-DNA antibodies in serum.

63 Deposition of anti-DNA antibodies in the kidney contributes to the pathogen

64 ominance, appearance of anti-double-stranded DNA antibodies in young adulthood, intravascular deposit

65 asma C4d, Bb, C5b-9 and anti-double-stranded DNA antibody in distinguishing patients with from those

66 eled antibody to evaluate deposition of anti-DNA antibody in the kidney and the successful use of a p

67 s mice from renal deposition of the R4A anti-DNA antibody in vivo.

68 d mice express high-affinity, unmutated anti-DNA antibodies, indicating that naive B cells that are n

69 that treatment of mesangial cells with anti-DNA antibodies induced high expression of neutrophil gel

70 g of the single chain Fv fragment of an anti-DNA antibody known to penetrate into living cells and ti

71 r patients with RA, 92% used either the anti-DNA antibody level or complement C3 level to monitor pat

72 mponent C3 and elevated anti-double-stranded DNA antibody levels at baseline improved in some, but no

73 counts, Ig levels, and anti-double-stranded DNA antibody levels were available as part of the clinic

74 m IgG antichromatin and anti-double-stranded DNA antibody levels were lower in NZM.Baff(-/-) .April(-

75 tibody-producing B cells, reduced serum anti-DNA antibody levels, retarded the development of nephrit

76 k this study to determine if pathogenic anti-DNA antibodies may also contribute to renal damage by di

77 ndicate that the renal pathogenicity of anti-DNA antibodies may be attributed in part to their abilit

78 uggest that a significant proportion of anti-DNA antibodies may cross-react with renal antigens and b

79 Our findings indicate that anti-DNA antibodies may promote important neuropathologic mec

80 The mechanism by which anti-DNA antibodies mediate lupus nephritis has yet to be con

81 s and the production of high titer ss and ds DNA antibodies of the IgG subclass that are not normally

82 Anti-DNA antibodies often play an important role in disease p

83 fluorescently stained eDNA with either anti-DNA antibodies or an ultrasensitive cell-impermeant dye,

84 reduce serum levels of anti-double-stranded DNA antibodies or renal immune complexes but did decreas

85 G anti-chromatin and/or anti-double-stranded DNA antibodies or with amounts of these autoantibodies d

86 test results were identified with respect to DNA antibody or C3 levels.

87 Specifically, no patient developed anti-DNA antibody or muscle enzyme elevations.

88 no changes in serum levels of IgG, IgG anti-DNA antibodies, or V(H)4-34 antibodies during the study.

89 ciated with anti-Ro and anti-double-stranded DNA antibodies (P = 4.6 x 10(-18) and P = 2.9 x 10(-16)

90 The structural underpinnings of anti-DNA antibody pathogenicity and antibody-DNA recognition,

91 Anti-DNA antibodies play important roles in the pathogenesis

92 ly reduced the frequency of IgG and IgG anti-DNA antibody-producing B cells, and these changes persis

93 opes induced CD8(+) T cells that killed anti-DNA antibody-producing B cells, reduced serum anti-DNA a

94 NZW F1 mice and evaluated the effect on anti-DNA antibody-producing B cells.

95 ed key disease manifestations including anti-DNA antibody production and glomerulonephritis.

96 nucleic acids stimulates interferon and anti-DNA antibody production in SLE.

97 plexes and autoreactive T-cell help for anti-DNA antibody production suggest novel directions for the

98 nors induced lupus with anti-double stranded DNA antibodies, proteinuria, and immune complex glomerul

99 vels of anti-Scl-70 and anti-double-stranded DNA antibodies (r = 0.558, P < 0.001).

100 y to a hybridized 76-base tag DNA with a tag DNA/antibody ratio of 50:1.

101 e compared with previously published data on DNA-antibody recognition.

102 uble-check its selectivity, two specific RNA-DNA antibodies recognizing miRNA-DNA heteroduplexes, ant

103 Anti-double stranded (ds) DNA antibodies represent a pathogenic autospecificity in

104 and its levels inversely correlate with anti-DNA antibody response.

105 algia and fever did not relapse, and anti-ds DNA antibody returned to normal during a follow-up perio

106 increase in the number of high-affinity anti-DNA antibody-secreting B cells in the spleens of E(2)-tr

107 treatment, and the frequency of Ig and anti-DNA antibody-secreting B cells was analyzed by enzyme-li

108 f 3 patients, and a 10-fold decrease in anti-DNA antibody-secreting cell lines was found after treatm

109 antibody with no DNA binding capability, and DNA antibody simultaneously with blocking peptide.

110 ental parameters such as the amount of input DNA, antibody specificity, ChIP enrichment and sequencin

111 une liver disease and greater titers of anti-DNA antibodies than did males, and 2-7 times more cells

112 nd had higher titers of anti-double-stranded DNA antibodies than wild-type MRL/lpr mice.

113 ignificantly higher renal deposition of anti-DNA antibody than of antibody without DNA binding capabi

114 cept, we address a problem of detecting anti-DNA antibodies that are characteristic of systemic lupus

115 ixed TCDM also reduced the formation of anti-DNA antibodies that are observed typically in male mice

116 SLE patients produce anti-DNA antibodies that crossreact with NMDA receptors and a

117 ed TCDM also prevented the formation of anti-DNA antibodies that is typically observed in male mice o

118 heavy chain of a potentially pathogenic anti-DNA antibody that antibody affinity for dsDNA does not a

119 with R4A, a pathogenic mouse monoclonal anti-DNA antibody that deposits in glomeruli.

120 related positively with anti-double-stranded DNA antibody titers among SLE patients and with rheumato

121 (P < 0.0001) and median anti-double-stranded DNA antibody titers from 106 to 42 IU/ml (P < 0.0001), a

122 D resulted in increased anti-double-stranded DNA antibody titers in lupus-prone mice.

123 e presence of proteinuria, hypertension, and DNA antibody titers were reviewed with respect to diseas

124 gene-expressing B cells, elevated serum anti-DNA antibody titers, and glomerular immunoglobulin depos

125 ssociated with enhanced anti-double-stranded-DNA antibody titers.

126 ced atherosclerosis and anti-double-stranded DNA antibody titers.

127 lupus erythematosus, recent studies of anti-DNA antibody transgenic mice clearly demonstrate that an

128 Positivity for anti-double-stranded DNA antibodies was associated with the expression levels

129 riation in the level of anti-double-stranded DNA antibody was different in individual patients.

130 ddress these issues for anti-single-stranded DNA antibodies, we have determined the 2.1 A crystal str

131 Anti-double-stranded DNA antibodies were associated with renal disease and ap

132 compared with (+/+) mice, but levels of anti-DNA antibodies were comparable in all groups.

133 Accordingly, anti-double-stranded DNA antibodies were elevated in patients with symptomati

134 y inhibitor were injected into mice and anti-DNA antibodies were measured by enzyme-linked immunosorb

135 and CH50 and titers of anti-double-stranded DNA antibodies were normalized after treatment with eith

136 t triggers the formation of IgG anti-histone/DNA antibodies, when expressed on the B6 background as a

137 Moreover, anti-DNA antibodies with this cross-reactivity mediate apopto

138 Anti-double-stranded DNA antibodies, with a mean onset 2.2 years before the d